4DMEDICAL LIMITED (4DX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

4DX - 4DMEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.12
Index: ALL-ORDS | ALL-TECH

4DMedical is a global medical technology company specialising in the treatment of lung disease through respitory imaging and analysis. The company has facilities in Melbourne and Los Angeles. It listed on the ASX in 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.61

24 May
2024

0.015

OPEN

$0.60

2.52%

HIGH

$0.62

155,471

LOW

$0.60

TARGET
$1.15 88.5% upside
OTHER COMPANIES IN THE SAME SECTOR
AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
4DX: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 10.5 - 8.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-10.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.7 M
Book Value Per Share xxxxxxxxxxxxxxx20.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-22.7 M
Net Profit Margin xxxxxxxxxxxxxxx-4,378.04 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-48.04 %
Return on Invested Capital xxxxxxxxxxxxxxx-44.84 %
Return on Assets xxxxxxxxxxxxxxx-37.62 %
Return on Equity xxxxxxxxxxxxxxx-48.04 %
Return on Total Capital xxxxxxxxxxxxxxx-62.62 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-23.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx70 M
Price To Book Value xxxxxxxxxxxxxxx3.24

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx224.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx25 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx7 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

29/02/2024

1

Buy

$1.10

80.33%

4DMedical's Imbio acquisition has completed and will provide some 'much needed' revenue over the coming twelve months, according to Bell Potter.

The broker anticipates solid progress on multiple commercialisation opportunities over 2024, including anticipating first revenues from its Philips collaboration within the year.

The company reported total first half revenue of $7.8m, comprising $0.4m in software as a service revenue, while revenue loss for the half totalled -$14.9m. 

The Buy rating is retained and the target price decreases to $1.10 from $1.25.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -8.20 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -8.40 cents.

4DX STOCK CHART